Class summary at a glance.

Every drug in the HMG-CoA Reductase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 6tracked in Part D
CY24 Part D spend: $2.33Bcombined across class
Total Rx claims: 184.9M59.0M unique beneficiaries
Generic mfrs (active): 70across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Atorvastatin

Brand: Lipitor · 110.8M Part D claims (CY24) · 34.5M beneficiaries · First FDA approval: 1996-12-17

22 generic mfrs 0 plans require PA

Low NADAC$0.025

→

Avg plan cost$0.397

Part D spend $1.20B 16× spread, current vs floor

Class share

52%

of class CY24 spend

View profile →

Rosuvastatin

Brand: Crestor · 47.9M Part D claims (CY24) · 16.3M beneficiaries · First FDA approval: 2016-07-19

18 generic mfrs 0 plans require PA

Low NADAC$0.035

→

Avg plan cost$0.269

Part D spend $716.1M 8× spread, current vs floor

Class share

31%

of class CY24 spend

View profile →

Simvastatin

Brand: ZOCOR · 22.1M Part D claims (CY24) · 6.9M beneficiaries · First FDA approval: 2006-12-20

11 generic mfrs 5 plans require PA

Low NADAC$0.028

→

Avg plan cost$0.395

Part D spend $190.2M 14× spread, current vs floor

Class share

of class CY24 spend

View profile →

Pitavastatin

Brand: Livalo · 466K Part D claims (CY24) · 159K beneficiaries · First FDA approval: 2017-02-03

8 generic mfrs 0 plans require PA

Low NADAC$1.16

→

Avg plan cost$2.99

Part D spend $182.6M 3× spread, current vs floor

Class share

of class CY24 spend

View profile →

Lovastatin

3.7M Part D claims (CY24) · 1.2M beneficiaries · First FDA approval: 2001-12-17

7 generic mfrs 0 plans require PA

Low NADAC$0.038

→

Avg plan cost$0.046

Part D spend $38.5M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Ezetimibe and Simvastatin

Brand: VYTORIN · — Part D claims (CY24) · First FDA approval: 2017-04-26

4 generic mfrs 3 plans require PA

Low NADAC$0.318

→

Avg plan cost$1.79

Part D spend — 6× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.